Nasus Pharma

Company Overview

Snapshot

Founded in May 2019 by Udi Gilboa and Dr. Dalia Meggido, Nasus Pharma operates with 1–10 employees. The company has raised $25 million across two funding rounds. Nasus Pharma became public on NYSE in August 2025, marking a significant milestone in its development.

Business overview

Nasus Pharma is a clinical-stage biopharmaceutical company specializing in the development of powder-based intranasal products. Leveraging its proprietary microsphere technology, the company focuses on creating solutions for acute emergency situations, including opioid overdose and anaphylactic shock. Its product portfolio features intranasal naloxone (NS-001), intranasal epinephrine (NS-002), and Taffix, serving the Health Tech & Life Sciences sector, particularly within pharmaceuticals and drug delivery, across markets in the United States, Israel, and Europe.

Strategic signal

In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002, an intranasal epinephrine powder. The study demonstrated significantly superior and faster epinephrine delivery compared to EpiPen®, achieving an accelerated speed to therapeutic threshold. This outcome is a strong validation of Nasus Pharma's microsphere technology and its potential to offer a needle-free, rapid-acting alternative for anaphylaxis treatment, signaling a clear path towards pivotal studies and potential market disruption in emergency medicine.

Company Intelligence Q&A

When did Nasus Pharma become a public company?

Nasus Pharma became public on NYSE in August 2025.

What was a key finding from the Phase 2 clinical study of NS002?

In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002, an intranasal epinephrine powder, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen®.

What is the latest leadership appointment at Nasus Pharma?

In July 2026, Nasus Pharma appointed Brendan P. O'Grady, a pharmaceutical industry veteran, as Chief Executive Officer to lead the company's strategic growth.

What recent preclinical results did Nasus Pharma announce?

In June 2026, Nasus Pharma announced positive results from a preclinical pharmacokinetic and safety study of intranasal Ondansetron (NS003).

What was the outcome of the private placement in February 2026?

In February 2026, Nasus Pharma announced the closing of a $15.0 million private placement.